Sara Varnado, PharmD, BCPS, BCCP

Despite significant improvements in care, HF remains a progressive, complex disease process associated with significant hospital admissions and cost.

In the past decade, patient outcomes after PCI have improved considerably with the advent of the oral P2Y12 receptor antagonists clopidogrel, prasugrel and ticagrelor.